Alkermes PLC (ALKS)
| Market Cap | 4.88B |
| Revenue (ttm) | 1.20B |
| Net Income (ttm) | -61.65M |
| Shares Out | 164.14M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | 588.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,113,675 |
| Open | 29.69 |
| Previous Close | 29.56 |
| Day's Range | 29.39 - 30.21 |
| 52-Week Range | 21.24 - 33.00 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 32.39 (+9.0%) |
| Earnings Date | Jul 27, 2022 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia a... [Read more...]
Financial Performance
In 2021, Alkermes's revenue was $1.17 billion, an increase of 13.00% compared to the previous year's $1.04 billion. Losses were -$48.17 million, -56.55% less than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is 32.39, which is an increase of 9.02% from the latest price.
News
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR ...
Alkermes to Participate in the Goldman Sachs Healthcare Conference
DUBLIN , June 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wed...
Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affecte...
– Competitive Grants Program Application Period to Begin on June 15, 2022 – DUBLIN , June 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications fo...
Alkermes to Participate in the Jefferies Healthcare Conference
DUBLIN , June 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at...
Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types – – Company to Host Investor Webcast on June 6 at 8:00 a.m. E...
Why Is Alkermes (ALKS) Down 1.4% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Sarissa Condemns Poor Corporate Governance at Alkermes
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement regarding Alkermes plc (NASDAQ: ALKS): Sarissa is disappointed that our discussions with R...
Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D.
– Appoints Nancy J. Wysenski as New Lead Independent Director – – David W.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) ...
– Final Dataset from ARTISTRY-1 Clinical Trial to be Featured in an Oral Presentation – – Trial-in-Progress Posters From ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented – DUBLIN ,...
The Simple Ethos Behind Alkermes' Research, According To Its CEO
There's a simple ethos behind Alkermes' research decisions, Chief Executive Richard Pops says as the biotech stock reaches a fresh high. The post The Simple Ethos Behind Alkermes' Research, According To...
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Aw...
̶ Clinical, Epidemiology and Health Economics and Outcomes Research to Advance Understanding of Treatment Patterns and Patient Experiences ̶ DUBLIN , May 2, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq...
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
Why Alkermes Stock Is Jumping Today
The drugmaker beat Wall Street's expectations with its Q1 results.
Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Alkermes plc Reports First Quarter 2022 Financial Results
— First Quarter Revenues of $278.5 Million Reflect Strong Performance of LYBALVI®, ARISTADA® and VIVITROL® — — GAAP Loss per Share of $0.22 and Basic and Diluted Non-GAAP Earnings per Share of $0. 12 ...
Alkermes to Report First Quarter Financial Results on April 27, 2022
DUBLIN , April 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica
DUBLIN , April 19, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it commenced binding arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V....
Alkermes Presents New Data From Psychiatry Portfolio at 2022 Congress of the Schizophrenia International Research Soc...
– Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI® in Patients Early in Illness – DUBLIN , April 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new researc...
Alkermes to Participate in the Stifel 2022 CNS Days
DUBLIN , March 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Stifel 2022 CNS Days on Tue...
Alkermes (ALKS) Up 2.1% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Ca...
DUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interl...
Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.
Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer
Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant immunotherapy for advanced renal cell carcinoma (...